SCHEMBL13638489

SCHEMBL13638489

C=C1CC(Nc2nccc(-c3c[nH]c4c(C)cc(F)cc34)n2)CC(C)(C)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.43
RET P07949 8/20 0.40
CDK1 P06493 7/20 0.39
CCNB1 P14635 6/20 0.39
CDC7 O00311 3/20 0.39
JAK2 O60674 3/20 0.39
CCNB2 O95067 3/20 0.39
MAP4K4 O95819 3/20 0.39
PIM1 P11309 3/20 0.39
PRKACA P17612 3/20 0.39
FLT3 P36888 3/20 0.39
GSK3B P49841 3/20 0.39
JAK3 P52333 3/20 0.39
PIM3 Q86V86 3/20 0.39
CCNB3 Q8WWL7 3/20 0.39
HIPK2 Q9H2X6 3/20 0.39
MKNK2 Q9HBH9 3/20 0.39
IRAK4 Q9NWZ3 3/20 0.39
AKT3 Q9Y243 3/20 0.39
INSR P06213 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481970 0.88 AR (0.47) ARRETCDK1CCNB1CDC7
SCHEMBL13638549 0.88 RET (0.46) ARRETCDK1CCNB1CDC7
SCHEMBL13638322 0.85 RET (0.35) ARRETCDK1CCNB1CDC7
SCHEMBL13638328 0.85 RET (0.45) ARRETCDK1CCNB1CDC7
SCHEMBL13638485 0.85 RET (0.41) ARRETCDK1CCNB1CDC7
SCHEMBL13638484 0.85 MAPK8 (0.46) RETCDK1CCNB1CDC7JAK2
SCHEMBL13638447 0.83 RET (0.39) RETCDK1CCNB1CDC7JAK2
SCHEMBL13638546 0.82 RET (0.46) RETCDK1CCNB1CDC7JAK2
SCHEMBL13638444 0.81 DYRK1A (0.48) ARRETCDK1CCNB1CDC7
SCHEMBL13638597 0.81 RET (0.45) RETCDK1CCNB1CDC7JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed